Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane based chemotherapy in operable triple negative breast cancer: Identification of biologically-defined signatures predicting treatment impact

Annals of Oncology

Volumn 25, Issue 8, 2014, Pages 1570-1577

  Nabholtz, J M ^a,b,c   Abrial, C ^a,b,c   Mouret Reynier, M A ^a,d   Dauplat, M M ^a,b   Weber, B ^e   Gligorov, J ^f   Forest, A M ^g   Tredan, O ^h   Vanlemmens, L ⁱ   Petit, T ^j   Guiu, S ^k   Van Praagh, I ^d   Jouannaud, C ^l   Dubray Longeras, P ^a,d   Tubiana Mathieu, N ^m   Benmammar, K E ^d   Kullab, S ^d   Bahadoor, M R K ^b,d   Radosevic Robin, N ^a,b   Kwiatkowski, F ^a,b   Desrichard, A ^a,b   Cayre, A ^a,c   Uhrhammer, N ^a,b   Chalabi, N ^a,b,c   Chollet, P ^a,b,n   Penault Llorca, F ^a,b   more..

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b Jean Perrin Comprehensive Cancer Centre   (France)

^c UMR 766   (France)

^d Medical Oncology   (France)

^e Institut de Cancérologie de Lorraine   (France)

^f HÔPITAL TENON   (France)

^g Montluçon hospital   (France)

^h CENTRE LÉON BÉRARD   (France)

ⁱ Oscar Lambret Comprehensive Cancer Center   (France)

^j Paul Strauss Comprehensive Cancer Center   (France)

^k Georges Francois Leclerc Cancer Centre   (France)

^l Jean Godinot Unicancer Institute   (France)

^m LIMOGES UNIVERSITY HOSPITAL   (France)

ⁿ INSERM   (France)

more..

Author keywords

Anti EGFR therapy; Neoadjuvant chemotherapy; Panitumumab; Pathological complete response; Predictive biomarkers; Triple negative breast cancer

Indexed keywords

ANTIEMETIC AGENT; BIOLOGICAL MARKER; BRCA1 PROTEIN; CD8 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 8; DOCETAXEL; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MONOCLONAL ANTIBODY KI 67; PANITUMUMAB; PROGESTERONE RECEPTOR; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FOXP3; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; MONOCLONAL ANTIBODY; TAXANE; TAXOID;

ACNE; ADULT; AGED; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRY SKIN; EDEMA; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NEUTROPENIA; OPERABLE TRIPLE NEGATIVE BREAST CANCER; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; SINGLE NUCLEOTIDE POLYMORPHISM; STRIA; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VOMITING; CANCER RESISTANCE; CD8+ T LYMPHOCYTE; CELL DENSITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; EGFR GENE; GENE FREQUENCY; HUMAN CELL; LYMPHOCYTE COUNT; MUTATIONAL ANALYSIS; PREMENOPAUSE; SCORING SYSTEM; TUMOR ASSOCIATED LEUKOCYTE; TUMOR SUPPRESSOR GENE; ADJUVANT THERAPY; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOADJUVANT THERAPY; PILOT PROJECTS; PROGNOSIS; TAXOIDS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905192459     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu183     Document Type: Article

References (30)

1. Penault-Llorca F, Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol 2012; 23 Suppl 6: vi19-22
2. von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804
3. Corkery B, Crown J, Clynes M, O'Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009; 20: 862-867
4. Baselga J, Gomez P, Greil R et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31: 2586-2592
5. Baselga J, Albanell J, Ruiz A et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005; 23: 5323-5333
6. Coyne CP, Ross MK, Bailey JG. Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition. J Drug Target 2009; 17: 474-489
7. Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24: 5664-5671
8. Chevallier B, Roche H, Olivier JP et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16: 223-228
9. Sataloff DM, Mason BA, Prestipino AJ et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995; 180: 297-306
10. [Recommendations for the immunohistochemistry of the hormonal receptors on paraffin sections in breast cancer. Update 1999. Group for Evaluation of Prognostic Factors using Immunohistochemistry in Breast Cancer (GEFPICS-FNCLCC)]. Ann Pathol 1999; 19: 336-343
11. Penault-Llorca F, Vincent-Salomon A, Bellocq JP et al. [Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]. Ann Pathol 2010; 30: 357-373
12. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145
13. Lakhani SR, Ellis IO, Schnitt SJ et al. WHO classification of tumors of the breast, 4th Edition. International Agency for Research on Cancer 2012
14. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374
15. Kwiatkowski F, Girard M, Hacene K, Berlie J. [Sem: a suitable statistical software adaptated for research in oncology]. Bull Cancer 2000; 87: 715-721
16. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281
17. Huober J, von Minckwitz G, Denkert C et al. Effect of neoadjuvant anthracyclinetaxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124: 133-140
18. von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23: 2676-2685
19. Heitz F, Harter P, Lueck HJ et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009; 45: 2792-2798
20. Lips EH, Mulder L, Oonk A et al. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer 2013; 108: 2172-2177
21. Generali D, Leek R, Fox SB et al. EGFR mutations in exons 18-21 in sporadic breast cancer. Ann Oncol 2007; 18: 203-205
22. Reis-Filho JS, Pinheiro C, Lambros MB et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006; 209: 445-453
23. Park HS, Jang MH, Kim EJ et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol 2014
24. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113
25. West NR, Milne K, Truong PT et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 2011; 13: R126
26. Litzenburger BC, Creighton CJ, Tsimelzon A et al. High IGF-IR activity in triplenegative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res 2011; 17: 2314-2327
27. Hartog H, Horlings HM, van der Vegt B et al. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Res Treat 2011; 129: 725-736
28. Jones HE, Goddard L, Gee JM et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004; 11: 793-814
29. Woelfle U, Sauter G, Santjer S et al. Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res 2004; 10: 2670-2674
30. Laakso M, Tanner M, Nilsson J et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 2006; 12: 4185-4191